Dermatologic Surgery



755-nm Q-switched Alexandrite laser as a treatment for melanonychia caused by onychomycosis

Journal:	Dermatologic Surgery
Manuscript ID	DS-00359-2016.R1
Manuscript type:	Letter and Communication
Date Submitted by the Author:	n/a
Complete List of Authors:	Lee, Sang Ju; Yonsei Star Skin & Laser Clinic, Dermatology Seok, Joon; Chung-Ang University College of Medicine, Department of Dermatology Park, Kui Young; Chung-Ang University College of Medicine, Department of Deramtology Seo, Seong Jun; Chung-Ang University College of Medicine, Department of Dermatology
Key Words:	755-nm Q-switched Alexandrite laser, Melanonychia



755-nm Q-switched Alexandrite laser as a treatment for melanonychia <u>caused by</u> <u>onychomycosis</u>

Sang Ju Lee¹, MD, PhD, Joon Seok², MD, Kui Young Park², MD, PhD, Seong Jun Seo², MD, PhD

¹Yonsei Star Skin & Laser Clinic, Seoul, Korea

²Departments of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea

Running title: 755-nm Q-switched Alexandrite laser as a treatment for melanonychia

Funding sources: None

Conflicts of interest: None declared

Word count: 948

Number of figures: 4

Number of references: 5

Keywords: 755-nm Q-switched Alexandrite laser, Melanonychia

Corresponding author: Kui Young Park, M.D., Ph.D.

Department of Dermatology, Chung-Ang University Hospital, 224-1 Heukseok-dong, Dongjak-gu, Seoul 06973, Korea

Tel.: +82.2-6299-1525

Fax: +82.2-823-1049

E-mail: momo920@daum.net

Introduction

Melanonychia is defined as brown or black pigmentation on a nail caused by melanin and other exogenous pigments. While the most common causes are benign nevi, trauma, onychomycosis, or medications, melanonychia may be a result of a subungual melanoma. When it is the result of a benign condition, patients may desire treatment for aesthetic reasons. The 755-nm Alexandrite Q-switched laser causes highly selective destruction of pigment-laden cells because the wavelength is highly absorbed by melanin relative to other optically absorbing structures in the skin. This laser is effective for both epidermal and dermal pigmented lesions.¹ Here, we describe two cases of melanonychia combined with onychomycosis that were treated using a single session of 755-nm Alexandrite laser with successful resolution.

Case report

Case 1

A 58-year-old Korean woman presented with longitudinal black pigmentation with fungal infection on the right big toe nail (Figure 1A). We treated the onychomycosis first with a 5% amorolofine nail lacquer (Loceryl[®], Galderma Ltd., Watford, UK) and 1,064-nm Nd:YAG laser (PinpointeTM FootLaserTM, Nuvolase Inc., Chico, CA). There was improvement of distal onycholysis and yellowish discoloration, but the longitudinal black pigmentation remained. We treated the longitudinal melanonychia with a 755-nm Q-switched Alexandrite laser (AlexTriVantage, Candela Laser Corporation, Wayland, MA, USA) using a 3-mm spot size and 50-nanosecond pulse duration with 6 J/cm². At the follow-up visit 1 month after a single treatment, the patient showed marked improvement in the hyperpigmentation (Figure 1B).

There were no side effects from any of the laser treatments.

Case 2

A 57-year-old woman visited our clinic with yellowish hyperkeratotic change of the left big toe nail and a longitudinal black pigmentation with nearly total dusky yellow-brownish color change on the right big toe nail (Figure 2A). She was first treated with amorolofine nail lacquer and 1,064-nm Nd:YAG laser for onychomycosis. The left big toe nail showed improvement but the black pigmentation of the right big toe nail showed very little improvement. The pigmented lesion was treated with a 755-nm Q-switched Alexandrite laser using a 3-mm spot size and 50-nanosecond pulse duration with 6 J/cm², and the lesion was totally resolved with no remaining black pigmentation on the right big toe nail (Figure 2B).

Discussion

Melanonychia, a medical condition in which the nail plate has a pigmentation band that is either black or brown in color, is a diagnostic challenge. The most serious disease of the nail unit, melanoma, primarily presents with melanonychia. However, melanonychia most often occurs as a result of benign etiologies such as nail matrix melanocytic activation, nail matrix melanocytic hyperplasia, and nail invasion by melanin-producing pathogens. In <u>a recent</u> Korean study, the most common cause was subungual hemorrhage, followed by nail matrix nevus, trauma-induced pigmentation, nail apparatus lentigo, and ethnic-type nail pigmentation. In the case of fungal melanonychia, the lesions most commonly involving the toenails, yellowish streaks with jagged borders composed of spikes are observed in addition to the dark pigment streak with distal widening.²

Dermatologic Surgery

If melanonychia is secondary to systemic and/or dermatologic disease, treatment of the underlying condition is helpful. If the condition is caused by a certain drug the recommendation is to stop taking that particular medication and the lesion will fade following withdrawal. In cases where there is a suspicion of melanoma, the doctor will recommend a biopsy of the lymph nodes to be performed as well. The management of melanoma of the nail unit requires complete excision of the tumor, which may require amputation of part of the digit. If the melanonychia is caused by a benign condition and there are no other symptoms associated with the condition, generally no further treatment will be recommended by the specialist. However, <u>in the author's clinical practices, some</u> affected patients want to eliminate the pigmented lesion for cosmetic, psychological, and social reasons.

In the two cases presented here, the yellowish and hyperkeratotic lesions improved after combined treatment for onychomycosis but the longitudinal black pigmentation remained. Fungal melanonychia is a relatively uncommon nail infection caused by species of fungus that produce melanin pigment, but the number of organisms implicated as etiologic agents of fungal melanonychia is increasing.³ These fungal melanonychia are often not responsive to traditional antifungal therapy. There is growing evidence that melanin may play an important role in the pathogenesis of fungal melanonychia, suggesting that inhibitors of melanin biosynthesis might reduce the pathogenic potential of many fungi and may be an effective adjunct to antifungal therapy.⁴

The 755-nm Q-switch Alexandrite laser is known to induce selective photothermolysis of pigmented lesions because absorption of laser energy by melanin predominates over absorption by hemoglobin at these wavelengths. Previous studies have shown excellent absorption by black pigment.^{1,5} Laser treatment was performed for black nail pigmentation in two patients using the 755-nm Q-switched Alexandrite laser set at an energy of 6.0 J/cm²

Dermatologic Surgery

with a 3-mm spot size, and there was marked clearance of pigmentation of the nails with a single laser treatment in both patients. Transient whitening of the nail surface was observed immediately after irradiation, but recovered within 1 day, and mild pain was observed during treatment without any anesthesia, but disappeared within several minutes. There were no other post-treatment changes such as onycholysis or onychodystrophy.

Physicians should always consider that some patients with melanonychia face a cosmetic, social and psychological burden and would want to remove the lesion. We should keep in mind that we must exclude melanoma before treating melanonychia for cosmetic purpose. When it is the result of a benign condition, the 755-nm Q-switched Alexandrite laser may be considered a reasonable therapeutic option for the treatment of these pigmented lesions. Further controlled clinical trials involving larger numbers of patients are needed for the optimization of treatment protocols and confirmation of the efficacy of treatment.

References

1. Trafeli JP, Kwan JM, Meehan KJ, Domankevitz Y, et al. Use of a long-pulse alexandrite laser in the treatment of superficial pigmented lesions. Dermatol Surg 2007;33:1477-82.

2. Jin H, Kim JM, Kim GW, Song M, et al. Diagnostic criteria for and clinical review of melanonychia in Korean patients. J Am Acad Dermatol 2016;74:1121-7.

3. Perrin C, Baran R. Longitudinal melanonychia caused by trichophyton rubrum. Histochemical and ultrastructural study of two cases. J Am Acad Dermatol 1994;31:311-6.

4. Finch J, Arenas R, Baran R. Fungal melanonychia. J Am Acad Dermatol 2012;66:830-41.

5. Moreno-Arias GA, Bulla F, Vilata-Corell JJ, Camps-Fresneda A. Treatment of widespread segmental nevus spilus by Q-switched alexandrite laser (755 nm, 100 nsec). Dermatol Surg 2001;27:841-3.

Figure Legend

Figure 1. (A) Longitudinal black pigmentation with fungal infection on the right big toe nail. (B) One month after a single treatment with a 755-nm Q-switched Alexandrite laser, the patient showed marked improvement in hyperpigmentation.

Figure 2. (A) Yellowish hyperkeratotic change in left big toe nail and longitudinal black pigmentation with nearly total dusky yellow-brownish colored changes on the right big toe nail. (B) One month after a single treatment with 755-nm Q-switched Alexandrite laser the lesion had resolved resulting in no black pigmentation on the right big toe nail.




Figure 1. (A) Longitudinal black pigmentation with fungal infection on the right big toe nail. (B) One month after a single treatment with a 755-nm Q-switched Alexandrite laser, the patient showed marked improvement in hyperpigmentation.

94x35mm (300 x 300 DPI)




Figure 2. (A) Yellowish hyperkeratotic change in left big toe nail and longitudinal black pigmentation with nearly total dusky yellow-brownish colored changes on the right big toe nail. (B) One month after a single treatment with 755-nm Q-switched Alexandrite laser the lesion had resolved resulting in no black pigmentation on the right big toe nail.

115x48mm (300 x 300 DPI)

CONFLICT OF INTEREST STATEMENT TO BE SIGNED BY ALL AUTHORS

Thank you for your submission to Dermatologic Surgery. The Conflict of Interest Statement we are asking you to complete may seem daunting, onerous and overly invasive of your privacy. Please be assured that the intent of the statement is none of these. This statement is in line with those required for authors submitting manuscripts to other journals. They have just become a fact of modern medical life.

The purpose of the Statement is to inform all interested parties of any significant affiliations or relationships you may have with any commercial enterprise. By having this information, readers may draw their own conclusions as to whether statements or conclusions you have made may have been influenced by the relationship.

1. Were you loaned any equipment, materials or medications for this study? Yes No $\sqrt{}$

2. Were you given any equipment, materials or medications for this study? Yes $_$ No \checkmark

Yes No 3. Did you receive any funding to support your research for this article?

4. Were you provided with any honoraria, payment or other compensation for your work on this study? Yes No -----

5. Did you receive any stock options, stock ownership or other valuable materials in conjunction with this study form any source whatsoever? Yes _____ No ____

6. Did you receive any outside financial support for travel or lectures to present the information covered in this study? Yes ____ No \bigvee

7. Do you have any financial relationship with any entity, which may closely compete with the medications, materials or instruments covered by your study? Yes No

8. Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in this study? Yes \sim No \sim

9. Does anyone in your immediate family have a conflict of interest that would be covered by any of the above questions? (This would/include closely held family trusts, limited liability corporations, etc.) Yes No

10. Is any part of this submission written by someone other than the named authors (ghost written)? Yes No 🗸

COMMENTS

If you checked YES to any of the above, please identify these potential conflicts below. Please be specific. If you have any doubts about the nature of your conflict, please contact William P. Coleman, III, MD, Editor- In-Chief. If necessary, attach an additional page for more comments.

I hereby grant permission for any such information, or an appropriate summary thereof, to be published in Dermatologic Surgery with the manuscript if the manuscript is accepted for publication.

F	El.
SIGNED:	
DATE: 2016.	6.1

PRINTED NAME:	San	g Ju	Lee
FAX TO EDITORIAL OF	FICE/	AT 1	-504-885-2512

Manuscript Number _____ (Assigned After Submission)

CONFLICT OF INTEREST STATEMENT TO BE SIGNED BY ALL AUTHORS

Thank you for your submission to Dermatologic Surgery. The Conflict of Interest Statement we are asking you to complete may seem daunting, onerous and overly invasive of your privacy. Please be assured that the intent of the statement is none of these. This statement is in line with those required for authors submitting manuscripts to other journals. They have just become a fact of modern medical life.

The purpose of the Statement is to inform all interested parties of any significant affiliations or relationships you may have with any commercial enterprise. By having this information, readers may draw their own conclusions as to whether statements or conclusions you have made may have been influenced by the relationship.

1. Were you loaned any equipment, materials or medications for this study? Yes ____ No

Were you loaned any equipment, materials or medications for this study? Yes _____ No____
Were you given any equipment, materials or medications for this study? Yes _____ No____

Yes Not 3. Did you receive any funding to support your research for this article?

4. Were you provided with any honoraria, payment or other compensation for your work on this study? Yes ____ No ___

5. Did you receive any stock options, stock ownership or other valuable materials in conjunction with this study form any source whatsoever? Yes _____ No _____

6. Did you receive any outside financial support for travel or lectures to present the information covered in this study? Yes _____ No _____

7. Do you have any financial relationship with any entity, which may closely compete with the medications, materials or instruments covered by your study? Yes $_$ No \lor

8. Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in this study? Yes ____ No __

9. Does anyone in your immediate family have a conflict of interest that would be covered by any of the above questions? (This would include closely held family trusts, limited liability corporations, etc.) Yes _____ No _____

10. Is any part of this submission written by someone other than the named authors (ghost written)? Yes No V

COMMENTS

If you checked YES to any of the above, please identify these potential conflicts below. Please be specific. If you have any doubts about the nature of your conflict, please contact William P. Coleman, III, MD, Editor- In-Chief. If necessary, attach an additional page for more comments.

I hereby grant permission for any such information, or an appropriate summary thereof, to be published in Dermatologic Surgery with the manuscript if the manuscript is accepted for publication.

SIGNED:	4
DATE: 2	016.6

PRINTED NAME: John Seolc FAX TO EDITORIAL OFFICE AT 1-504-885-2512

Manuscript Number (Assigned After Submission)

CONFLICT OF INTEREST STATEMENT TO BE SIGNED BY ALL AUTHORS

Thank you for your submission to *Dermatologic Surgery*. The Conflict of Interest Statement we are asking you to complete may seem daunting, onerous and overly invasive of your privacy. Please be assured that the intent of the statement is none of these. This statement is in line with those required for authors submitting manuscripts to other journals. They have just become a fact of modern medical life.

The purpose of the Statement is to inform all interested parties of any significant affiliations or relationships you may have with any commercial enterprise. By having this information, readers may draw their own conclusions as to whether statements or conclusions you have made may have been influenced by the relationship.

1. Were you loaned any equipment, materials or medications for this study? Yes $___$ No \checkmark

2. Were you given any equipment, materials or medications for this study? Yes $___No$

3. Did you receive any funding to support your research for this article? Yes <u>Nov</u>

4. Were you provided with any honoraria, payment or other compensation for your work on this study? Yes _____ No _____

5. Did you receive any stock options, stock ownership or other valuable materials in conjunction with this study form any source whatsoever? Yes ____ No ____

6. Did you receive any outside financial support for travel or lectures to present the information covered in this study? Yes _____ No ____

7. Do you have any financial relationship with any entity, which may closely compete with the medications, materials or instruments covered by your study? Yes ____ No ____

8. Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in this study? Yes _____ No ____

9. Does anyone in your immediate family have a conflict of interest that would be covered by any of the above questions? (This would include closely held family trusts, limited liability corporations, etc.) Yes _____No

10. Is any part of this submission written by someone other than the named authors (ghost written)? Yes _____ No____

COMMENTS

If you checked YES to any of the above, please identify these potential conflicts below. Please be specific. If you have any doubts about the nature of your conflict, please contact William P. Coleman, III, MD, Editor- In-Chief. If necessary, attach an additional page for more comments.

I hereby grant permission for any such information, or an appropriate summary thereof, to be published in Dermatologic Surgery with the manuscript if the manuscript is accepted for publication.

		1.
SIGNED:		11
DATE:	201	1.6

PRINTED NAME: Kui Yom Park FAX TO EDITORIAL OFFICE AT 1/-504-885-2512

Manuscript Number

_____ (Assigned After Submission)

CONFLICT OF INTEREST STATEMENT TO BE SIGNED BY ALL AUTHORS

Thank you for your submission to Dermatologic Surgery. The Conflict of Interest Statement we are asking you to complete may seem daunting, onerous and overly invasive of your privacy. Please be assured that the intent of the statement is none of these. This statement is in line with those required for authors submitting manuscripts to other journals. They have just become a fact of modern medical life.

The purpose of the Statement is to inform all interested parties of any significant affiliations or relationships you may have with any commercial enterprise. By having this information, readers may draw their own conclusions as to whether statements or conclusions you have made may have been influenced by the relationship.

1. Were you loaned any equipment, materials or medications for this study? Yes \sim No \vee

2. Were you given any equipment, materials or medications for this study? Yes No

Yes No. 3. Did you receive any funding to support your research for this article?

4. Were you provided with any honoraria, payment or other compensation for your work on this study? Yes No V

5. Did you receive any stock options, stock ownership or other valuable materials in conjunction with this study form any source whatsoever? Yes _____ No ____

6. Did you receive any outside financial support for travel or lectures to present the information covered in this study? Yes _____ No _____

7. Do you have any financial relationship with any entity, which may closely complete with the medications, materials or instruments covered by your study? Yes No V

8. Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in this study? Yes No V

9. Does anyone in your immediate family have a conflict of interest that would be covered by any of the above questions? (This would include closely held family trusts, limited liability corporations, etc.) Yes No

10. Is any part of this submission written by someone other than the named authors (ghost written)? Yes No \vee

COMMENTS

If you checked YES to any of the above, please identify these potential conflicts below. Please be specific. If you have any doubts about the nature of your conflict, please contact William P. Coleman, III, MD, Editor- In-Chief. If necessary, attach an additional page for more comments.

I hereby grant permission for any such information, or an appropriate summary thereof, to be published in Dermatologic Surgery with the manuscript if the manuscript is accepted for publication.

SIGNED:		1
DATE:	2016	6.1

PRINTED NAME:SeventFAX TO EDITORIAL OFFICE (AT 1-504-885-2512)

Manuscript Number (Assigned After Submission)